𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Stature loss following treatment for Wilms tumor

✍ Scribed by Hogeboom, Charissa J. ;Grosser, Stella C. ;Guthrie, Katherine A. ;Thomas, Patrick R. ;D'Angio, Giulio J. ;Breslow, Norman E.

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
147 KB
Volume
36
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A multicenter evaluation of a proprietar
A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: A five-year follow-up
✍ Wadden, Thomas A. ;Frey, David L. πŸ“‚ Article πŸ“… 1997 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 45 KB πŸ‘ 2 views

## Objective: The traditional goal of obesity therapy has been the reduction of body weight to an ideal standard. patient difficulties, however, in reaching this goal have led to a reassessment of weight loss criteria. the institute of medicine of the national academy of sciences recently proposed

Recombinant human soluble tumor necrosis
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
✍ Alessandro Busca; Franco Locatelli; Filippo Marmont; Cristina Ceretto; Michele F πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 2 views

## Abstract Etanercept is a recombinant human soluble tumor necrosis factor (TNF‐α) receptor fusion protein that inhibits TNF‐α, a major mediator in the pathogenesis of graft‐versus‐host disease (GVHD). The purpose of our study was to evaluate the safety and efficacy of etanercept therapy in 21 pat